Showing 1672 results
-
Press release /Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common…
-
Press release /Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection…
-
Press release /Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818,…
-
Story /Raising awareness of the ways in which prostate cancer can affect the sexual minority and gender minority communities.
-
Story /By growing human tumors in mice, NIBR develops a unique system that seeks to mimic clinical trials of cancer drugs
-
Story /Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.
-
Story /Genome editing advances drug discovery in biomedical research.
-
Story /Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.